Natural Killer Cells Therapies- Competitive Landscape,Technology and Pipeline Analysis, 2017

 Published On: Nov, 2017 |    No of Pages: 207 |  Published By: DelveInsight | Format: PDF
Request Free Sample
“Natural Killer Cells Therapies- Competitive Landscape, Technology and Pipeline Analysis, 2017”, emphasizes on the currently active NK cell therapy products and NK cell augmenters in research and development.  

The report covers 20+ companies, which are active in this field with 40+ products and many different technologies. This report covers NK cell based therapies and drugs that augment (enhance or activate) the NK cells. The report provides in-depth analysis on the Natural Killer Cell based therapies profiles along with the augmenting therapies covering their pre-clinical and clinical studies, collaborations details and deal values, technologies and targeted antigens. The report provides the NK Cell based therapies licensing opportunities, acquisitions, market drivers and barriers followed by SWOT Analysis.

Reports Highlights:
NK cell Therapy Pipeline scenario which includes NK cell therapies and NK cell augmenting therapies.
Collaborations & partnering deals
Current Prominent Research Areas and Key Players
Pipeline product profiles NK Cell therapy Technologies and NK cell Augmenting Therapies
Licensing opportunities
Market Drivers and Barriers

Scope
Overview of the global NK cell therapy and NK cell augmenting therapies pipeline scenario, products and associated companies information
Coverage of global NK cell therapies and drugs that enhance the activity of NK under development
Competitive landscape of products for key players and related indications
Coverage of licensors, collaborators and development partners, deal terms and deal values estimation
Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities
Highlights of licensing & collaboration opportunities and funding details
Highlights of latest NK cell therapy technologies and NK cell augmenting therapies and innovative companies
Key topics covered include strategic competitor assessment, barriers and drivers in the market along with SWOT analysis
Report Introduction  1
Reports Highlights  1
Scope  1
Executive Summary  12
Natural Killer Cells Therapy Overview  13
Leading Companies with NEXT Generation Technologies  16
Market Drivers  17
Market Barriers  19
SWOT Analysis  20
Natural Killer Cells Based Therapies  21
Natural Killer Cells Based Therapies and Targets  22
NK Cells Based Therapy Collaborations  24
Collaborations and Deal Year  24
Collaborations and Deal value  24
Licensing Agreement for Future Developments  25
Institutes involved in NK cells based therapies  26
NK Cells Based Therapies and Technologies  28
Clinical trials & Completion Year  30
Phase II Trials  30
Phase I Trials  31
Pipeline Therapeutics for Natural Killer Cells Based Therapies  32
Therapeutics under Development by Companies  33
Mid Stage Products (Phase II)  34
Comparative Analysis  34
Early Stage Products (Phase I and IND)  47
Comparative Analysis  47
Pre-Clinical Products  58
Comparative Analysis  58
Therapeutic Assessment of Natural Killer Cell Therapies  99
Assessment by Monotherapy Products  99
Assessment by Combination Products  100
Assessment by Route of Administration  101
Assessment by Stage and Route of Administration  102
Assessment by Molecule Type  103
Assessment by Stage and Molecule Type  104
Assessment by Domain  105
Assessment by Stage and Domain  106
Natural Killer Cell Augmenters  107
Targets of Natural Killer Cells Augmenters and Their Analysis  108
NK Cells Augmenters Based Therapy Collaborations
Collaborations and Deal Year  109
Collaborations and Deal value  110
Licensing Agreement for future development of NK Cell Augmenters Therapy  111
Financing details of NK cells augmenters based therapies  113
Companies received Grants for NK cells augmenters based therapies  
Designation  
Institutes involved in NK Cells Augmenters Based Therapies  
NK Cells Augmenters Based Therapies and Technologies  
Clinical trials & Completion Year  
Phase III Trials  
Phase II Trials  
Phase I Trials  
Pipeline Therapeutics for Natural Killer Cells Augmenters(Enhancers & Activators)  
Therapeutics under Development by Companies  
NK Cells Enhancers  
NK Cells Activators  
Natural Killer Cell Enhancers  
Late Stage Products (Phase III)  
Comparative Analysis  
Mid Stage Products (Phase II)  
Comparative Analysis  
Early Stage Products (Phase I)  
Comparative Analysis  
Pre –clinical Products  
Comparative Analysis  
Natural Killer Cells Activators  
Mid Stage Products (Phase II)  
Comparative Analysis  
Early Stage Products (Phase I)  
Comparative Analysis  
Pre –clinical Products  
Comparative Analysis  
Therapeutic Assessment of Natural Killer Cell Augmenters (Enhancers & Activators)  
Assessment by Monotherapy Products  
Assessment by Route of Administration  
Assessment by Stage and Route of Administration  
Assessment by Molecule Type  
Assessment by Stage and Molecule Type  
Assessment by Domain  
Assessment by Stage and Domain  
Appendix  
Report Methodology
DelveInsight Consulting Services  
About DelveInsight  
Contact Us  
Disclaimer

List of Tables

Table 1:SWOT analysis of NK Cells Based Therapies& Augmenters, 2017  
Table 2: Targets and Number of Products  
Table 3:Natural Killer Cells based therapies -Target Antigens and Companies  
Table 4:Collaboration and Deal Values for NK cell therapy, 2017  
Table 5:Licensing Agreement for future development of NK Cell based Therapies, 2017  
Table 6: Institute involved in NK Cells based Therapies, 2017  
Table 7 : Companies and their technologies for NK Cells Based Therapies, 2017  
Table 8: Natural Killer Cell based therapies-Study Completion Date of Phase II Drugs, 2017  
Table 9: Natural Killer Cell based therapies-Study Completion Date of Phase I Drugs, 2017  
Table 10:Number of Products Under Development for Natural Killer Cells Therapies, 2017  
Table 11: Number of Products under development by Companies, 2017  
Table 12: Mid Stage Products (Phase II), 2017  
Table 13: Early Stage Products (Phase I), 2017  
Table 14: Pre-Clinical Products, 2017  
Table 15: Assessment by Monotherapy Products, 2017  
Table 16:Assessment by Combination Products, 2017  
Table 17: Assessment by Route Of Administration, 2017  
Table 18:Assessment by Stage and Route Of Administration, 2017  
Table 19: Assessment by Molecule Type, 2017  
Table 20: Assessment by Stage and Molecule Type, 2017  
Table 21:Assessment by Stage of development and Domain, 2017  
Table 22:Assessmentby Stage of development and Domain, 2017  
Table 23:Targets and Number of Products  
Table 24:Natural Killer Cells Augmenters based therapies -Target Antigens and Companies  
Table 25:Collaboration and Deal Values for NK cell Augmenters therapy, 2017  
Table 26: Licensing Agreement for future development of NK Cell Augmenters Therapy, 2017  
Table 27:Companies of NK cells augmenters based therapies financing for future developments, 2017  
Table 28:Companies of NK cells Augmenters Received Grants, 2017  
Table 29: Analysis of Natural Killer Cells Augmenters On The Basis of Designation, 2017  
Table 30: Institute involved in NK Cells Augmenters, 2017  
Table 32: Natural Killer Cell Augmenters based therapies-Study Completion Date of Phase III Drugs, 2017  
Table 33: Natural Killer Cell Augmenters based therapies-Study Completion Date of Phase II Drugs, 2017  
Table 34: Natural Killer Cell Augmenters based therapies-Study Completion Date of Phase I Drugs, 2017  
Table 35:Number of Products Under Development for Natural Killer Cells Augmenters(Enhancers & Activators), 2017
Table 36: Number of Products under development by Companies, 2017  
Table 37: Number of Products under development by Companies, 2017  
Table 38: Late Stage Products (Phase III), 2017  
Table 39: Mid Stage Products (Phase II), 2017  
Table 40: Early Stage Products (Phase I), 2017  
Table 41: Pre –clinical Products (Phase I), 2017  
Table 42: Mid Stage Products (Phase II), 2017  
Table 43: Early Stage Products (Phase I), 2017  
Table 44: Pre –clinical Products (Phase I), 2017  
Table 45: Assessment by Monotherapy Products, 2017  
Table 46: Assessment by Route Of Administration, 2017  
Table 47:Assessment by Stage and Route Of Administration, 2017  200
Table 48: Assessment by Molecule Type, 2017  
Table 49: Assessment by Stage and Molecule Type, 2017  
Table 50:Assessment by Stage of development and Domain, 2017  
Table 51:Assessmentby Stage of development and Domain, 2017

 List of Figures

Figure 1: Mechanism of action  
Figure 2:NK Cells Therapy Collaborations and Deal Year, 2014-2016  
Figure 3:Natural Killer Cell based therapies-Study Completion Date of Phase II Drugs, 2017  
Figure 4:Natural Killer Cell based therapies-Study Completion Date of Phase I Drugs, 2017  
Figure 5:Number of Products under Development for Natural Killer Cells Therapies,2017  
Figure 6: Mid Stage Products (Phase II), 2017  
Figure 7:Early Stage Products (Phase I), 2017  
Figure 8:Pre-Clinical Products, 2017  
Figure 9: Assessment by Monotherapy Products,2017  
Figure 10: Assessment by Combination Products, 2017  
Figure 11: Assessment by Route of Administration, 2017  
Figure 12: Assessment by Stage and Route of Administration,2017  
Figure 13: Assessment by Molecule Type,2017  
Figure 14: Assessment by Stage and Molecule Type,2017  
Figure 15: Assessment by Domain, 2017  
Figure 16:Assessmentby Stage and Domain, 2017  
Figure 17:NK Cells Augmenters Based Therapy Collaborations and Deal Year, 2017  
Figure 18:NK Cells Augmenters based therapies designation and Number of Products, 2017  
Figure 19:Natural Killer Cell Augmenters based therapies-Study Completion Date of Phase III Drugs, 2017  
Figure 20:Natural Killer Cell Augmenters based therapies-Study Completion Date of Phase II Drugs, 2017  
Figure 21:Natural Killer Cell Augmenters based therapies-Study Completion Date of Phase I Drugs, 2017  
Figure 23:Late Stage Products (Phase III), 2017  
Figure 24: Mid Stage Products (Phase II), 2017  
Figure 25:Early Stage Products (Phase I), 2017  
Figure 26:Pre –clinical Products (Phase I), 2017  
Figure 27: Mid Stage Products (Phase II), 2017  
Figure 28:Early Stage Products (Phase I), 2017  
Figure 29:Pre –clinical Products (Phase I), 2017  
Figure 30: Assessment by Monotherapy Products,2017  
Figure 31: Assessment by Route of Administration, 2017  
Figure 32: Assessment by Stage and Route of Administration,2017  
Figure 33: Assessment by Molecule Type,2017  
Figure 34: Assessment by Stage and Molecule Type,2017  
Figure 35: Assessment by Domain, 2017  
Figure 36:Assessmentby Stage and Domain, 2017

If the above report does not have the information suitable for your business, we can provide custom research that can be lucrative for your business or enhance your profession.